Jun 17, 2025
Оfftopic Community
Оfftopic Community
Forums
New posts
Search forums
What's new
Featured content
New posts
New media
New media comments
New resources
New profile posts
Latest activity
Media
New media
New comments
Search media
Resources
Latest reviews
Search resources
Members
Current visitors
New profile posts
Search profile posts
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Install the app
Install
Forums
Information & News
RSS News
Health and Fitness
GlaxoSmithKline And XenoPort Receive FDA Complete Response Letter For Horizant™ (GSK1
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="tD33NAt" data-source="post: 2087617" data-attributes="member: 124445"><p>GlaxoSmithKline (NYSE: GSK) and XenoPort, Inc. (Nasdaq: XNPT) Wednesday received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for Horizant™(gabapentin enacarbil) Extended-Release Tablets, an investigational non-dopaminergic treatment for moderate-to-severe primary Restless Legs Syndrome (RLS). A Complete Response letter is issued by the FDA's Center of Drug Evaluation and Research when the review of a file is completed and questions remain that preclude the approval of the NDA in its current form...<a href="http://feedads.g.doubleclick.net/~a/oBdlbOhRbJ-501CqT_luBan4uVM/0/da" target="_blank"><img src="http://feedads.g.doubleclick.net/~a/oBdlbOhRbJ-501CqT_luBan4uVM/0/di" alt="" class="fr-fic fr-dii fr-draggable " data-size="" style="" /></a></p><p><a href="http://feedads.g.doubleclick.net/~a/oBdlbOhRbJ-501CqT_luBan4uVM/1/da" target="_blank"><img src="http://feedads.g.doubleclick.net/~a/oBdlbOhRbJ-501CqT_luBan4uVM/1/di" alt="" class="fr-fic fr-dii fr-draggable " data-size="" style="" /></a></p><p></p><p><img src="http://feeds.feedburner.com/~r/mnt/healthnews/~4/lofFbawfoB8" alt="" class="fr-fic fr-dii fr-draggable " data-size="" style="" /></p><p></p><p><a href="http://feedproxy.google.com/~r/mnt/healthnews/~3/lofFbawfoB8/3xV4" target="_blank">More...</a></p></blockquote><p></p>
[QUOTE="tD33NAt, post: 2087617, member: 124445"] GlaxoSmithKline (NYSE: GSK) and XenoPort, Inc. (Nasdaq: XNPT) Wednesday received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for Horizant™(gabapentin enacarbil) Extended-Release Tablets, an investigational non-dopaminergic treatment for moderate-to-severe primary Restless Legs Syndrome (RLS). A Complete Response letter is issued by the FDA's Center of Drug Evaluation and Research when the review of a file is completed and questions remain that preclude the approval of the NDA in its current form...[URL="http://feedads.g.doubleclick.net/~a/oBdlbOhRbJ-501CqT_luBan4uVM/0/da"][IMG]http://feedads.g.doubleclick.net/~a/oBdlbOhRbJ-501CqT_luBan4uVM/0/di[/IMG][/URL] [URL="http://feedads.g.doubleclick.net/~a/oBdlbOhRbJ-501CqT_luBan4uVM/1/da"][IMG]http://feedads.g.doubleclick.net/~a/oBdlbOhRbJ-501CqT_luBan4uVM/1/di[/IMG][/URL] [IMG]http://feeds.feedburner.com/~r/mnt/healthnews/~4/lofFbawfoB8[/IMG] [url=http://feedproxy.google.com/~r/mnt/healthnews/~3/lofFbawfoB8/3xV4]More...[/url] [/QUOTE]
Insert quotes…
Name
Verification
Please enable JavaScript to continue.
Loading…
Post reply
Top